Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 15;11(5):228.
doi: 10.21037/atm-22-6266. Epub 2023 Jan 9.

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer

Simone Nardin  1   2 , Lucia Del Mastro  1   2
Affiliations
Editorial

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer

Simone Nardin et al. Ann Transl Med. .
No abstract available

Keywords: Breast cancer; Sacituzumab Govitecan (SG); Trastuzumab Deruxtecan; antibody-drug conjugate (ADC); hormone-receptor positive.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-6266/coif). LDM received grants or contracts from Eli Lilly, Novartis, Roche, Daiichi Sankyo, and Seagen; fees or honoraria from Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, MSD, Seagen, Gilead, Pierre Fabre, Eisai, Exact Science, and Ipsen; and participation on a data safety monitoring or advisory board from Novartis, Roche, Eli Lilly, Pfizer, Daiichi Sankyo, Exact Science, Gilead, Pierre Fabre, Eisai, and AstraZeneca, outside the submitted work. The other author has no conflicts of interest to declare.

Comment on

References

    1. Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 2022;66:15-23. 10.1016/j.breast.2022.08.010 - DOI - PMC - PubMed
    1. Pandit P, Patil R, Palwe V, et al. Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. Eur J Breast Health 2020;16:39-43. 10.5152/ejbh.2019.4997 - DOI - PMC - PubMed
    1. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489-502. 10.1016/j.breast.2014.08.009 - DOI - PubMed
    1. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 2021;39:3959-77. 10.1200/JCO.21.01392 - DOI - PMC - PubMed
    1. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32:1475-95. 10.1016/j.annonc.2021.09.019 - DOI - PubMed